MAP6D1

Across TCGA pan-cancer cohorts, MAP6D1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MAP6D1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MAP6D1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAP6D1 expression acts as an unfavorable survival marker.

GBM are the cancer types where MAP6D1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.289	0.450	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MAP6D1–GBM (OS)

Open the GBM breakdown →